Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Change in Accured Expenses (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Change in Accured Expenses for 6 consecutive years, with $8.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 143.98% year-over-year to $8.6 million, compared with a TTM value of -$23.4 million through Dec 2025, up 54.78%, and an annual FY2024 reading of $7.5 million, down 80.64% over the prior year.
  • Change in Accured Expenses was $8.6 million for Q4 2025 at Roivant Sciences, down from $12.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $37.6 million in Q3 2023 and bottomed at -$50.0 million in Q2 2023.
  • Average Change in Accured Expenses over 5 years is -$450800.0, with a median of $5.7 million recorded in 2022.
  • The sharpest move saw Change in Accured Expenses skyrocketed 281.76% in 2021, then plummeted 376.83% in 2023.
  • Year by year, Change in Accured Expenses stood at $35.6 million in 2021, then plummeted by 83.97% to $5.7 million in 2022, then plummeted by 376.83% to -$15.8 million in 2023, then dropped by 23.58% to -$19.5 million in 2024, then soared by 143.98% to $8.6 million in 2025.
  • Business Quant data shows Change in Accured Expenses for ROIV at $8.6 million in Q4 2025, $12.5 million in Q3 2025, and -$25.0 million in Q2 2025.